Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

Inflammatory Bowel Diseases. 2011, 17(1), 127-140

View abstract

Authors

Loftus E Jr, Johnson S, Wang S, Wu EQ, Mulani PM, Chao J